Custom Library Synthesis

Rapid access to high-quality compound libraries plays a crucial role in accelerating drug discovery processes. Allmpus has established itself as a prominent leader in library synthesis, producing over 1000+ individual purified compounds annually in substantial quantities, available as dry samples. Our expertise enables us to deliver efficient library synthesis services with quick turnaround times. Our competitive advantages stem from the following:

• Vision to become the world’s largest stock of building blocks. With a staggering inventory of building blocks available in our own stock, we have an unparalleled resource to immediately commence the synthesis project and create compound libraries of exceptional quality, boasting an extensive array of designs, novelty, and innovative structural motifs
• Knowledge of the building block reactivity. To optimize efficiency and conserve valuable scaffold material, we leverage our internal statistical data to avoid undertaking dubious syntheses that are prone to failure. This data-driven approach allows us to make informed decisions, avoiding wasteful processes and ensuring that our resources are allocated effectively
• Unprecedented capabilities in parallel synthesis. Our unmatched expertise in parallel synthesis, backed by validated protocols, enables the rapid production of over 1 500 compounds per day.

• Targeted libraries contains drug-like molecules, including EGFR, CDK8, CDK9, MEK1, MEK3, JAK2 & BRAF are available for screening
• Synthesis capabilities for synthesis of large Libraries
• Allmpus Libraries includes 1000+ NCE with novelty, excellent properties & clear IP space is available for screening
• 260 NCE’S (Targeted NCE’S) Now available & Suitable for multiple screening purposes
• Good diversity, higher screening probability and novelty
• High purity(>95%), which meets the purity requirements for drug screening
• Professional team of synthesis, calculation, and drug experts

Targeted and focused libraries are used to screen therapeutic targets to find hit compounds that may further develop into drugs. The design of targeted and focused libraries usually utilize structural information about target or target families. If no such structural information is available, chemical genomic models combining sequence and mutagenesis data can be used to predict the nature of the binding site. When no structural data is available, the third method usually used is to use the properties of the target ligands to obtain focus libraries from them by scaffold hopping.